Escitalopram in breast cancer patients
Phase 2
Recruiting
- Conditions
- Malignant neoplasm of breast.Malignant neoplasm of breast
- Registration Number
- IRCT20150630022991N14
- Lead Sponsor
- Babol University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 40
Inclusion Criteria
Newly diagnosed breast cancer patients
With depression and anxiety symptoms
Exclusion Criteria
Previous history of high mood
Suicidal thoughts
Mental retardation
Dementia
Substance dependence
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pain severity. Timepoint: At the beginning of the study and four weeks after intervention. Method of measurement: Visual Analogue Scale.;Depressive symptoms. Timepoint: At the beginning of the study and four weeks after intervention. Method of measurement: Hospital Anxiety and Depression Scale.;Anxiety symptoms. Timepoint: At the beginning of the study and four weeks after intervention. Method of measurement: Hospital Anxiety and Depression Scale.
- Secondary Outcome Measures
Name Time Method Escitalopram- related side effects. Timepoint: In four weeks of intervention period. Method of measurement: Medical visit.